A Phase 2 Clinical Trial To Evaluate The Immune Restoration Potential Of Lenalidomide For Patients With CLL-Associated Immunodeficiency
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 03 May 2017
At a glance
- Drugs Lenalidomide (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Pharmacodynamics
- 26 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Sep 2016 Planned initiation date changed from 1 Apr 2015 to 1 Feb 2017.
- 11 Jan 2016 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020 as per ClinicalTrials.gov record.